Efficacy of Denosumab for Treatment of Pain in Fibrous Dysplasia and McCune‐Albright Syndrome: A Systematic Review
Authors' conclusion
In patients with FD/MAS undergoing treatment with denosumab, pain improved in 81.8% of patients, and analgesic requirement decreased in greater than half of patients.
Study context
- Population
- Patients with fibrous dysplasia (FD), with or without McCune-Albright syndrome (MAS), treated with denosumab
- Participants
- 88 patients16 studies
- Outcome
- Change in pain score (quantitative pain scales), proportion of pain responders (≥ 2-point reduction or overall subjective improvement in pain), and change in analgesic requirement
Methodological detailsPRISMA guidelines
- PRISMA guidelines
Pooled result
As reported in the abstract
Pain
Mean pain score decrease (points on a 10-point scale)
3.51
Pain responders
81.8%
Reduction or cessation of analgesic use
51.7%
Safety
Adverse events related to denosumab
- Any adverse event
- 55.8%
- Hypocalcemia
- 11.6%
- Hypophosphatemia
- 8.1%
- Rebound hypercalcemia after denosumab discontinuation
- 8 patients (9.3%)
- Severe rebound hypercalcemia
- 4
Original publication
Efficacy of Denosumab for Treatment of Pain in Fibrous Dysplasia and McCune‐Albright Syndrome: A Systematic Review. Clin Endocrinol (Oxf). Published 19 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →